Loading Astec LifeSciences…
| ₹ Cr | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue | 84 | 159 | 125 | 91 | 120 |
| Operating profit | -12 | -3 | -7 | -22 | -6 |
| Operating margin | -14.0% | -1.6% | -5.8% | -24.7% | -5.1% |
| Net profit | -19 | -8 | -16 | -33 | -16 |
| Net margin | -22.4% | -4.9% | -12.6% | -36.3% | -13.5% |
| EPS (₹) | -8.40 | -3.48 | -7.04 | -16.85 | -8.20 |
Quarters are labelled by period end.
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 446 | 378 | 458 | 628 |
| Operating profit | -49 | -109 | -42 | 44 |
| Operating margin | -11.1% | -28.9% | -9.1% | 6.9% |
| Net profit | -81 | -135 | -47 | 26 |
| Net margin | -18.2% | -35.6% | -10.3% | 4.1% |
| EPS (₹) | -37.79 | -68.71 | -23.75 | 12.94 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Total assets | 942 | 881 | 975 | 979 |
| Total liabilities | 551 | 646 | 605 | 560 |
| Shareholders’ equity | 391 | 235 | 369 | 419 |
| Total debt | 449 | 555 | 494 | 341 |
| Cash & equivalents | 10 | 1 | 0 | 0 |
| Debt / equity | 1.15 | 2.36 | 1.34 | 0.81 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Operating cash flow | -81 | -8 | 10 | 75 |
| Capital expenditure | -6 | -22 | -135 | -117 |
| Free cash flow | -86 | -30 | -125 | -43 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Return on equity | -20.7% | -57.4% | -12.7% | 6.1% |
| Return on assets | -8.6% | -15.3% | -4.8% | 2.6% |
| Net margin | -18.2% | -35.6% | -10.3% | 4.1% |
Source: Yahoo Finance. Figures in ₹ crore unless stated.
No analyst data available for ASTEC. Finnhub coverage is limited for some India-listed stocks.